Checking in with Imvax ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers
CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and previews key P2b data that is currently scheduled for mid-2025.